Neurocarrus
Private Company
Funding information not available
Overview
Neurocarrus is a private, preclinical-stage biotech founded in 1986 and based in Seattle, Washington. The company is advancing a novel, modular protein delivery platform called APOLLO to create therapeutics that precisely target neurons, aiming to treat pain and neurodegeneration without the addiction risk or systemic side effects of current standards of care. Its pipeline includes lead asset N-001 for acute/surgical pain, NL-17 for migraines, and several earlier-stage programs for chronic pain and other indications. The company is currently pre-revenue and appears to be raising capital through a crowdfunding initiative.
Technology Platform
APOLLO platform: a modular protein delivery system with three independent components (Translocator C2II, Payload e.g., C2I actin remodeler, Targeting C1 receptor binder) for combinatorial engineering of therapeutics that specifically target and enter neurons to modify intracellular function.
Opportunities
Risk Factors
Competitive Landscape
Neurocarrus competes in the non-opioid analgesic space with companies developing NaV channel inhibitors, anti-NGF antibodies, TRP channel modulators, and novel delivery systems. Its differentiation lies in its precise neuronal targeting via engineered proteins to modify intracellular signaling, a mechanism distinct from most small molecules and antibodies blocking extracellular targets.